This study is now recruiting

Follow the link to check your eligibility and register your interest

Summary

The KAPPA trial is a study of ketamine and cognitive behavioural therapy (CBT) as treatment for people using methamphetamine and seeking to reduce their substance use.

The study involves twice-weekly visits for 4 weeks, and then four follow-up visits over a period of 6 months. These will take place at St Vincent's Hospital Sydney. Only residents of Sydney will be able to participate due to face-to-face study requirements.

If you have additional questions related to the trial, please contact a member of the study team by phone or by email.

Complete our survey to check your eligibility for the trial:

Check your eligibility

Investigators

Prof Nadine Ezard

SVHS/UNSW/National Centre for Clinical Research on Emerging Drugs

Brendan Clifford

SVHS / UNSW/National Centre for Clinical Research on Emerging Drugs

Dr Krista Siefried

UNSW/National Centre for Clinical Research on Emerging Drugs

A/Prof Gillinder Bedi

University of Melbourne/Orygen

Dr Alexandre Guerin

University of Melbourne/Orygen

Dr Jonathan Brett

SVHS/Alcohol and Drug Service/Clinical Pharmacology and Toxicology

Dr Mike Millard

SVHS/UNSW/Clinical Research Unit for Anxiety and Depression

Dr Robert May

SVHS/Alcohol and Drug Service

Elizabeth Knock

SVHS/Alcohol and Drug Service

Dr Liam Acheson

SVHS/UNSW/Alcohol and Drug Service/National Drug and Alcohol Research Centre

Dr Kathryn Fletcher

UNSW/National Centre for Clinical Research on Emerging Drugs